Threshold out-licenses TH302 to Merck Serono; Phase III trials fail and deal ends
Threshold Pharmaceuticals Inc. (cancer drug development) has granted Merck KGAA’s Merck Serono SA division rights to co-develop and exclusively sell globally its TH302, a hypoxia-targeted compound in Phase III trials for soft tissue sarcoma, and in additional studies for other cancers. Threshold retains an option to co-promote in the US, giving it the chance to receive 50% of the profits in that territory.
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com